Assessment of skin test with varicella-zoster virus antigen for predicting the risk of herpes zoster

Epidemiology and Infection

Volumn 141, Issue 4, 2013, Pages 706-713

  Okuno, Y ^a   Takao, Y ^a,b   Miyazaki, Y ^a   Ohnishi, F ^a   Okeda, M ^a   Yano, S ^a   Kumihashi, H ^a   Gomi, Y ^a   Maeda, K ^a   Ishikawa, T ^a   Mori, Y ^c,d   Asada, H ^e   Iso, H ^b   Yamanishi, K ^d  

^a The Research Foundation for Microbial Diseases of Osaka University   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^e NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell mediated immunity; herpes zoster; skin test; surrogate marker; varicella zoster virus

Indexed keywords

VIRUS ANTIGEN;

ADULT; AGE DISTRIBUTION; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ERYTHEMA; FEMALE; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROGNOSIS; RISK ASSESSMENT; SKIN EDEMA; SKIN TEST; VARICELLA ZOSTER VIRUS; VIRUS EXAMINATION;

AGED; AGED, 80 AND OVER; ANTIGENS, VIRAL; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; INCIDENCE; JAPAN; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; SKIN TESTS;

EID: 84874494369     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268812002671     Document Type: Article

References (24)

1. Hope-Simpson RE. The nature of herpes zoster: A longterm study and a new hypothesis. Proceedings of the Royal Society of Medicine 1965; 58: 9-20
2. Schmader K. Herpes zoster in older adults. Clinical Infectious Diseases 2001; 32: 1481-1486
3. Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine 2005; 352: 2271-2284
4. Sadaoka K, et al. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: Comparison between VZV skin test and interferon-c enzyme-linked immunospot assay. Journal of Infectious Diseases 2008; 198: 1327-1333
5. Kamiya H, et al. Diagnostic skin test reaction with varicella virus antigen and clinical application of the test. Journal of Infectious Diseases 1977; 136: 784-788
6. Baba K, et al. Studies with live varicella vaccine and inactivated skin test antigen: Protective effect of the vaccine and clinical application of the skin test. Pediatrics 1978; 61: 550-555
7. Asano Y, et al. Soluble skin test antigen of varicellazoster virus prepared from the fluid of infected cultures. Journal of Infectious Diseases 1981; 143: 684-692
8. Shiraki K, Yamanishi K, Takahashi M. Biologic and immunologic characterization of the skin-Test antigen of varicella-zoster virus. Journal of Infectious Diseases 1984; 149: 501-504
9. Hata S. Skin test with varicella-zoster virus antigen on herpes zoster patients. Archives of Dermatological Research 1980; 268: 65-70
10. Tanaka Y, et al. Skin test with varicella-zoster virus antigen for ophthalmic herpes zoster. American Journal of Ophthalmology 1984; 98: 7-10
11. Baba K, et al. Specificity of skin test with varicellazoster virus antigen in varicella-zoster and herpes simplex virus infection. Journal of Clinical Microbiology 1987; 25: 2193-2196
12. Ihara T, et al. Antibody response determined with antibody-dependent cell-mediated cytotoxicity (ADCC), naturalizing antibody, and varicella skin test in children with natural varicella and after varicella immunization. Acta Paediatrica Japonica 1991; 33: 43-49
13. Takahashi M, et al. Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction. Archives of Virology (Supplement) 2001; 17: 161-172
14. Takahashi M, et al. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003; 21: 3845-3853
15. Levin MJ, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases 2008; 197: 825-835
16. Takao Y, et al. Prospective cohort study of herpes zoster in Shozu County: The Shozu Herpes Zoster (SHEZ) Study. Journal of Epidemiology 2012; 22: 167-174
17. Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infection and Immunity 1981; 32: 24-27
18. Burke BL, et al. Immune responses to varicella-zoster in the aged. Archives of Internal Medicine 1982; 142: 291-293
19. Levin MJ, et al. Immune response of elderly individuals to a live attenuated varicella vaccine. Journal of Infectious Diseases 1992; 166: 253-259
20. Levin MJ, et al. Decline varicella-zoster virus (VZV)-specific cell-mediate immunity with increasing age and boosting with a high-dose VZV vaccine. Journal of Infectious Diseases 2003; 188: 1336-1344
21. Berger R, Luescher D, Just M. Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. Journal of Infectious Diseases 1984; 149: 647
22. Berger R, et al. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases 1998; 178 (SUPPL 1): S99-103
23. Levin MJ, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: Duration of booster effect. Journal of Infectious Diseases 1998; 178 (SUPPL 1): S109-112
24. Sato H, et al. Superiority of varicella skin test antigen over varicella-zoster virus glycoprotein in monitoring booster response to Oka varicella vaccine. Vaccine 2003; 22: 15-20